粪便微生物组与代谢组特征整合分析可区分非肝硬化NASH与健康对照人群
基于REGENERATE I303研究中279例经活检证实为非肝硬化NASH(F1-F3纤维化)美国患者的前瞻性粪便样本,行鸟枪法宏基因组测序并与3个健康对照队列比较,整合粪便胆汁酸绝对定量。调整BMI和年龄的逻辑回归识别12种NASH相关菌种,随机森林模型AUC为0.75-0.81;特定粪便胆汁酸在NASH中显著降低并与血浆C4水平相关;粪便胆汁酸对非肝硬化NASH与健康的区分优于血浆胆汁酸或肠道微生物组特征。
要点
- 调整BMI和年龄后识别出12种NASH相关菌种,随机森林模型AUC为0.75-0.81。
- 特定粪便胆汁酸在NASH中显著降低,并与血浆C4水平相关。
- 粪便胆汁酸水平区分非肝硬化NASH与健康优于血浆胆汁酸或肠道微生物组特征。
核心结论
- 这些结果可作为非肝硬化NASH的基线特征,用于比较预防肝硬化的治疗干预并识别基于微生物组的诊断生物标志物。
研究设计与样本
- 对REGENERATE I303研究中279例经活检证实为非肝硬化NASH(F1-F3纤维化)美国患者前瞻性收集的粪便样本行鸟枪法宏基因组测序,并与3个健康对照队列比较,整合粪便胆汁酸绝对定量。
主要发现
- 微生物群β多样性存在差异,调整BMI和年龄的逻辑回归识别出12种NASH相关菌种。
- 随机森林预测模型在受试者工作特征分析中AUC为0.75-0.81。
- 特定粪便胆汁酸在NASH中显著降低,并与血浆C4水平相关。
- 微生物基因丰度分析显示,对照组中127个基因增加(多涉及蛋白质合成),NASH中362个基因增加(多涉及细菌环境应答),错误发现率<0.01。
- 粪便胆汁酸水平区分非肝硬化NASH与健康可能优于血浆胆汁酸或肠道微生物组特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There is great interest in identifying microbiome features as reliable noninvasive diagnostic and/or prognostic biomarkers for non-cirrhotic NASH fibrosis. Several cross-sectional studies have reported gut microbiome features associated with advanced NASH fibrosis and cirrhosis, where the most prominent features are associated with cirrhosis. However, no large, prospectively collected data exist establishing microbiome features that discern non-cirrhotic NASH fibrosis, integrate the fecal metabolome as disease biomarkers, and are unconfounded by BMI and age. APPROACH AND RESULTS: Results from shotgun metagenomic sequencing performed on fecal samples prospectively collected from 279 US patients with biopsy-proven NASH (F1-F3 fibrosis) enrolled in the REGENERATE I303 study were compared to those from 3 healthy control cohorts and integrated with the absolute quantification of fecal bile acids. Microbiota beta-diversity was different, and BMI- and age-adjusted logistic regression identified 12 NASH-associated species. Random forest prediction models resulted in an AUC of 0.75-0.81 in a receiver operator characteristic analysis. In addition, specific fecal bile acids were significantly lower in NASH and correlated with plasma C4 levels. Microbial gene abundance analysis revealed 127 genes increased in controls, many involving protein synthesis, whereas 362 genes were increased in NASH many involving bacterial environmental responses (false discovery rate < 0.01). Finally, we provide evidence that fecal bile acid levels may be a better discriminator of non-cirrhotic NASH versus health than either plasma bile acids or gut microbiome features. CONCLUSIONS: These results may have value as a set of baseline characteristics of non-cirrhotic NASH against which therapeutic interventions to prevent cirrhosis can be compared and microbiome-based diagnostic biomarkers identified.
引用
- Carr RM, Li Y, Chau L, et al. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 2023. PMID: 37222264. doi:10.1097/HEP.0000000000000474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。